Name
- Masitinib.
Class of drug
- Protein-tyrosine kinase inhibitor.
Uses
Action
- Selectively inhibits the mutated form, in the juxtamembrane (JM) region, of the c-kit receptor.
- Also inhibits the Platelet Derived Growth Factor (PDGF) and the Fibroblast Growth Factor Receptor (FGFR3).
Indications
- Treatment of non-resectable canine mast cell tumors
(Grade 2 or 3) with confirmed mutation of the c-kit tyrosine kinase receptor. - For any mast cell tumor treatable by surgery, surgery should be the first choice of treatment.
Adverse reactions
Other reported reactions
- Mild to moderate gastrointestinal reactions (diarrhea and vomiting) with a mean duration of approximately 21 and 9 days respectively.
- Mild to moderate alopecia with a mean duration of approximately 26 days.
- Severe renal toxicity may occur in dogs with renal disorders at start of treatment (including high blood creatinine level or proteinuria ).
- Mild to severe anemia (aplastic/hemolytic) with a mean duration of approximately 7 days.
- Protein-loss syndrome (mainly due urinary protein losses).
- Mild or moderate neutropenia with a mean duration of approximately 24 days.
- Increase in aminotransferases (ALT or AST) with a mean duration of approximately 29 days.
- Other commonly observed adverse reactions were in most cases mild or moderate:
- Lethargy and asthenia (mean duration approximately 8 and 40 days respectively).
- Decreae in appetite or anorexia (mean duration 45 days and 18 days respectively).
- Cough (mean duration 23 days).
- Lymphadenopathy (mean duration 47 days).
- Edema (mean duration 7 days).
- Lipoma (mean duration 53 days).
- In case of adverse events following overdose, treatment should be discontinued until resolution, and then resumed at the recommended therapeutic dose level.
